Utah Medical Products extends tender offer for Utah Medical Products stock
Published on 10/18/2026 at 13:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOffer terms and reporting dates
- On October 5, 2026, Utah Medical Products extended its offer for 650,000 shares at USD 75.00.
- First-half 2026 revenue fell 12.3 percent to USD 17.3 million.
- Calendar third-quarter results are scheduled for October 22, 2026, before the October 27, 2026 tender deadline.
- Utah Medical Products stock last stood at USD 74.51 on Nasdaq on October 16, 2026.
Utah Medical Products (US9174881089) extended its tender offer on October 5, 2026, covering up to 650,000 common shares at USD 75.00 per share. According to StockTitan, the revised deadline is October 27, 2026, and the company cited its scheduled third-quarter results as an additional reason for the extension.
Tender terms and results date
The offer price remains USD 75.00, while the number of shares covered remains 650,000. The extension gives holders until 5:00 p.m. New York City time on October 27, 2026, to consider the offer and the company's calendar third-quarter results, scheduled for October 22, 2026, according to Yahoo Finance.
Chronology carries three figures
On July 23, 2026, Utah Medical Products reported second-quarter revenue of USD 8.53 million and diluted earnings per share of USD 0.84, as summarized by MarketBeat. On September 24, 2026, the company launched the offer for 650,000 shares at USD 75.00, according to StockTitan. On October 5, 2026, it extended the deadline to October 27, 2026.
What does the offer change?
The capital-return plan arrives alongside weaker operating figures. In the first half of 2026, revenue fell 12.3 percent to USD 17.3 million, operating income declined 17.9 percent to USD 5.2 million, and management projected a 10 percent to 13 percent revenue decline for 2026, according to Makkler Labs. The same analysis cited USD 87.5 million in cash and investments as of June 30, 2026, with no debt.
The next dates are fixed
The October 22, 2026 results date is the next operating checkpoint, while October 27, 2026 is the tender deadline. Together, the dates put the upcoming revenue and earnings figures directly alongside the USD 75.00 offer decision.
Stock valuation and market context
Utah Medical Products develops specialty medical devices for healthcare settings including labor and delivery and neonatal care, according to its Utah Medical Products investor-relations page. The stock last stood at USD 74.51 on Nasdaq on October 16, 2026 at 4:00 p.m. ET. Its market capitalization was USD 236.5 million, and its 52-week range was USD 53.66 to USD 76.89.
Market context: Market report Nasdaq Composite.
More news and analyses on Utah Medical Products stock are available on the company topic page.
